Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
ATAI atai Life Sciences	$2.33 +5.0%	$1.82	$1.03 ▼ $2.64	$466.79M	1.48	1.71 million shs	3.08 million shs
NKTR Nektar Therapeutics	$8.61 -1.4%	$10.09	$6.48 ▼ $22.79	$106.88M	0.55	141,686 shs	449,582 shs
OMER Omeros	$3.22 +0.3%	$4.87	$2.97 ▼ $13.60	$188.67M	2.2	692,140 shs	568,278 shs
PRTK Paratek Pharmaceuticals	$2.23	$2.22	$1.29 ▼ $3.65	$127.82M	1.7	724,253 shs	N/A

The 10 Best AI Stocks to Own in 2025

Wondering where to start (or end) with AI stocks? These 10 simple stocks can help investors build long-term wealth as artificial intelligence continues to grow into the future.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
ATAI atai Life Sciences	0.00%	+6.88%	+13.66%	+60.69%	+83.46%
NKTR Nektar Therapeutics	0.00%	-1.71%	-16.46%	-33.54%	-49.65%
OMER Omeros	0.00%	-9.30%	-2.13%	-64.62%	-21.27%
PRTK Paratek Pharmaceuticals	0.00%	0.00%	0.00%	0.00%	0.00%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	Dividend Strength	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
ATAI atai Life Sciences	3.1435 of 5 stars	3.7	3.0	0.0	0.0	2.8	2.5	0.6
NKTR Nektar Therapeutics	4.3301 of 5 stars	3.5	4.0	0.0	4.2	2.8	2.5	0.0
OMER Omeros	3.7085 of 5 stars	3.4	0.0	0.0	4.4	2.7	1.7	0.6
PRTK Paratek Pharmaceuticals	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
ATAI atai Life Sciences	3.33	Buy	$8.67	271.96% Upside
NKTR Nektar Therapeutics	3.00	Buy	$67.50	683.97% Upside
OMER Omeros	2.83	Moderate Buy	$18.00	459.01% Upside
PRTK Paratek Pharmaceuticals	0.00	N/A	N/A	N/A

Current Analyst Ratings Breakdown

Latest OMER, PRTK, NKTR, and ATAI Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
6/10/2025	OMER Omeros	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Buy	$9.00
5/20/2025	ATAI atai Life Sciences	Jefferies Financial Group Subscribe to MarketBeat All Access for the recommendation accuracy rating	Set Price Target		$5.00
5/20/2025	ATAI atai Life Sciences	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$10.00 ➝ $10.00
5/16/2025	OMER Omeros	Needham & Company LLC Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Hold ➝ Hold
5/13/2025	ATAI atai Life Sciences	Cantor Fitzgerald Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Strong-Buy
5/13/2025	OMER Omeros	D. Boral Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$36.00 ➝ $36.00
5/12/2025	NKTR Nektar Therapeutics	William Blair Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Market Perform
5/7/2025	OMER Omeros	D. Boral Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$36.00 ➝ $36.00
4/11/2025	NKTR Nektar Therapeutics	Jefferies Financial Group Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Hold ➝ Buy	$15.00 ➝ $30.00
4/11/2025	OMER Omeros	D. Boral Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$36.00 ➝ $36.00
4/1/2025	OMER Omeros	Needham & Company LLC Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Hold ➝ Hold

(Data available from 6/20/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
ATAI atai Life Sciences	$310K	1,505.78	N/A	N/A	$0.69 per share	3.38
NKTR Nektar Therapeutics	$87.25M	1.22	N/A	N/A	$4.94 per share	1.74
OMER Omeros	N/A	N/A	N/A	N/A	($3.15) per share	N/A
PRTK Paratek Pharmaceuticals	$160.27M	0.80	N/A	N/A	($3.08) per share	-0.72

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
ATAI atai Life Sciences	-$149.27M	-$0.91	N/A	N/A	N/A	N/A	-102.10%	-77.55%	8/12/2025 (Estimated)
NKTR Nektar Therapeutics	-$118.96M	-$9.60	N/A	N/A	N/A	-152.49%	-329.54%	-55.24%	8/6/2025 (Estimated)
OMER Omeros	-$156.82M	-$2.65	N/A	N/A	N/A	N/A	N/A	-59.68%	8/6/2025 (Estimated)
PRTK Paratek Pharmaceuticals	-$63.57M	-$1.10	N/A	∞	N/A	-35.44%	N/A	-40.05%	N/A

Latest OMER, PRTK, NKTR, and ATAI Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
5/15/2025	Q1 2025	OMER Omeros	-$0.60	-$0.65	-$0.05	-$0.58	$0.40 million	N/A
5/14/2025	Q1 2025	ATAI atai Life Sciences	-$0.19	-$0.15	+$0.04	-$0.15	N/A	$1.56 million
5/8/2025	Q1 2025	NKTR Nektar Therapeutics	-$2.70	-$3.30	-$0.60	-$0.24	$15.61 million	$10.46 million
3/31/2025	Q4 2024	OMER Omeros	-$0.71	-$0.63	+$0.08	-$0.54	$0.40 million	N/A

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
ATAI atai Life Sciences	N/A	N/A	N/A	N/A	N/A
NKTR Nektar Therapeutics	N/A	N/A	N/A	N/A	N/A
OMER Omeros	N/A	N/A	N/A	N/A	N/A
PRTK Paratek Pharmaceuticals	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
ATAI atai Life Sciences	0.08	4.07	4.07
NKTR Nektar Therapeutics	N/A	3.24	3.24
OMER Omeros	N/A	1.16	1.16
PRTK Paratek Pharmaceuticals	N/A	0.52	0.46

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
ATAI atai Life Sciences	28.41%
NKTR Nektar Therapeutics	75.88%
OMER Omeros	48.79%
PRTK Paratek Pharmaceuticals	53.60%

Insider Ownership

Company	Insider Ownership
ATAI atai Life Sciences	26.80%
NKTR Nektar Therapeutics	5.25%
OMER Omeros	12.90%
PRTK Paratek Pharmaceuticals	8.00%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
ATAI atai Life Sciences	80	200.34 million	146.65 million	Optionable
NKTR Nektar Therapeutics	220	12.41 million	11.76 million	Optionable
OMER Omeros	210	58.59 million	51.04 million	Optionable
PRTK Paratek Pharmaceuticals	268	57.32 million	52.74 million	Optionable

OMER, PRTK, NKTR, and ATAI Headlines

Recent News About These Companies

Optinose CEO and other top executives exit after company's acquisition by Paratek

May 23, 2025 | bizjournals.com

Paratek expands commercial portfolio with Optinose

May 22, 2025 | msn.com

OptiNose Shareholders Approve Merger with Paratek

May 18, 2025 | investing.com

Paratek Pharmaceuticals to Present Clinical Data on NUZYRA® (omadacycline) at the American Thoracic Society (ATS) 2025 International Conference

May 16, 2025 | globenewswire.com

How a Bucks County firm's multiyear pursuit of a partner led to a potential $330M deal

April 11, 2025 | bizjournals.com

Paratek Pharmaceuticals to Present New Data on NUZYRA® (omadacycline) at ESCMID Global 2025

April 10, 2025 | globenewswire.com

Paratek acquires Optinose, rhinosinusitis spray Xhance in deal worth up to $330M

March 21, 2025 | fiercepharma.com

Paratek Pharmaceuticals to acquire Optinose in $330M transaction

March 21, 2025 | markets.businessinsider.com

Paratek boosts commercial portfolio in move to buy Optinose and its nasal spray

March 20, 2025 | endpts.com

Optinose Shares Surge Premarket on Takeover Deal With Paratek

March 20, 2025 | marketwatch.com

Paratek Pharmaceuticals Announces Completion of U.S. Onshoring Program, Making NUZYRA® (omadacycline) the Only Novel Antibiotic with Domestic Supply and Manufacturing Capabilities

November 14, 2024 | globenewswire.com

Paratek Pharmaceuticals Announces Positive Top-Line Data from Phase 2b Study of Oral ...

November 9, 2024 | eagletribune.com

Paratek Pharmaceuticals Announces Positive Top-Line Data from Phase 2b Study of Oral Omadacycline (OMC) in Nontuberculous Mycobacterial (NTM) Abscessus Pulmonary Disease

November 8, 2024 | globenewswire.com

Paratek Pharmaceuticals Announces Presentation of Several New Studies of NUZYRA® (omadacycline) Across a Range of Serious Infections at IDWeek 2024

October 14, 2024 | globenewswire.com

Paratek Pharmaceuticals Completes Five-Year Microbiologic Surveillance Study of NUZYRA® (omadacycline) Demonstrating No Change in In Vitro Potency Against Indicated Pathogens

July 31, 2024 | globenewswire.com

Paratek looks to bolster pneumonia antibiotic Nuzyra with win in post-marketing study

July 19, 2024 | fiercepharma.com

Paratek Pharmaceuticals Announces Positive Top-line Efficacy and Safety Data from Post-Marketing Study of NUZYRA® (omadacycline) for Patients with Moderate to Severe Community-Acquired Bacterial Pneumonia

July 18, 2024 | globenewswire.com

Pharmaceuticals / Health Products Summary

April 4, 2024 | opensecrets.org

Paratek Reports Positive Data For Nuzyra As Post-exposure Prophylaxis Of Pulmonary Anthrax In NHPs

March 5, 2024 | markets.businessinsider.com

Mira Pharmaceuticals Stock (NASDAQ:MIRA) Dividends: History, Yield and Dates

February 24, 2024 | benzinga.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

View All

3 Defense Stocks That Will Profit From a Golden Dome
By Chris Markoch | May 30, 2025
View 3 Defense Stocks That Will Profit From a Golden Dome
Analysts Think These Stocks Could More Than Double in Value
By Nathan Reiff | May 23, 2025
View Analysts Think These Stocks Could More Than Double in Value
Intel’s Turnaround May Be the Best Bet No One’s Watching
By Jeffrey Neal Johnson | May 30, 2025
View Intel’s Turnaround May Be the Best Bet No One’s Watching
Broadcom Slides on Solid Earnings, AI Outlook Still Strong
By Leo Miller | June 6, 2025
View Broadcom Slides on Solid Earnings, AI Outlook Still Strong
Red Robin's Comeback: Q1 Earnings Spark Investor Hopes
By Jeffrey Neal Johnson | June 5, 2025
View Red Robin's Comeback: Q1 Earnings Spark Investor Hopes

OMER, PRTK, NKTR, and ATAI Company Descriptions

atai Life Sciences NASDAQ:ATAI

$2.33 +0.11 (+4.95%)

Closing price 06/18/2025 04:00 PM Eastern

Extended Trading

$2.35 +0.02 (+0.86%)

As of 06/18/2025 07:56 PM Eastern

Atai Life Sciences N.V., a clinical-stage biopharmaceutical company, develops and invests in various therapeutics to treat depression, anxiety, addiction, and other mental health disorders. Its product candidates include COMP360, a proprietary psilocybin which is in Phase 3 program; BPL-003, an intranasal formulation that is in Phase 2a and 2b clinical studies; TRD; VLS-01, an transmucosal film in Phase 1b clinical studies; and ELE-101, a serotonergic psychedelic that is in Phase 1/2a study, for the treatment of treatment resistant depression. The company also develop IBX-210, an intravenous formulation of ibogaine, and DMX-1002, an oral formulation of ibogaine indicated for the treatment of opioid use disorder; EMP-01, an oral formulation of an R-MDMA derivative being developed for the treatment of post-traumatic stress disorder; and EGX-A and EGX-B, psychedelic-like with novel, non-tryptamine structures with differentiated 5-HT receptor pharmacology. In addition, it offers RL-007, an orally bioavailable compound, which is a pro-cognitive neuromodulator for cognitive impairment associated with schizophrenia; and GRX-917, a deuterated etifoxine for the treatment of generalize anxiety disorder. Further, the company develops PCN-101, a subcutaneous formulation of R-ketamine, as a therapy for psychiatric indications initially focused on TRD; KUR-101, a formulation of deuterated mitragynine for the treatment of OUD; and RLS-01, indicated for treatment resistant depression. ATAI Life Sciences N.V. was founded in 2018 and is headquartered in Berlin, Germany with offices in New York and London.

Nektar Therapeutics NASDAQ:NKTR

$8.61 -0.12 (-1.37%)

Closing price 06/18/2025 04:00 PM Eastern

Extended Trading

$8.71 +0.10 (+1.21%)

As of 06/18/2025 07:39 PM Eastern

Nektar Therapeutics, a biopharmaceutical company, focuses on discovering and developing medicines in the field of immunotherapy in the United States and internationally. The company is developing rezpegaldesleukin, a cytokine Treg stimulant that is in phase 2 clinical trial for the treatment of systemic lupus erythematosus and ulcerative colitis, as well as phase 2b clinical trial to treat atopic dermatitis and psoriasis; and NKTR-255, an IL-15 receptor agonist, which is in phase 1 clinical trial to boost the immune system's natural ability to fight cancer. It has collaboration agreements with Takeda Pharmaceutical Company Ltd.; AstraZeneca AB; UCB Pharma S.A.; F. Hoffmann-La Roche Ltd; Bausch Health Companies Inc.; Pfizer Inc.; Amgen Inc.; UCB Pharma (Biogen); Bristol-Myers Squibb Company; Merck KGaA; and SFJ Pharmaceuticals, Inc. The company was incorporated in 1990 and is headquartered in San Francisco, California.

Omeros NASDAQ:OMER

$3.22 +0.01 (+0.31%)

Closing price 06/18/2025 04:00 PM Eastern

Extended Trading

$3.22 0.00 (0.00%)

As of 06/18/2025 04:15 PM Eastern

Omeros Corporation, a clinical-stage biopharmaceutical company, discovers, develops, and commercializes small-molecule and protein therapeutics, and orphan indications targeting immunologic diseases, including complement-mediated diseases, cancers, and addictive and compulsive disorders. The company's products under development include Narsoplimab (OMS721/MASP-2) that has completed pivotal trial for hematopoietic stem-cell transplant-associated thrombotic microangiopathy (TA-TMA); that is in Phase III clinical trial for the treatment of immunoglobulin A nephropathy (IgAN); and Phase II clinical trial to treat COVID-19. It also develops OMS1029 that is in phase I clinical trials for long-acting second-generation antibody targeting lectin pathway disorders; OMS906 that has completed phase II clinical trials for Paroxysmal nocturnal hemoglobinuria, complement 3 glomerulopathy, and other alternative pathway disorders; and OMS527 that is in phase I clinical trials for addictions and compulsive disorders, and movement disorders. In addition, the company's products under preclinical development comprise MASP-2, a pro-inflammatory protein target for the treatment of lectin pathway disorders; MASP-3 small-molecule inhibitors for alternative pathway disorders; and Adoptive T-Cell and Chimeric Antigen Receptor (CAR) T-Cell Therapies and Immunomodulators/Immunotoxins/Cancer Vaccines for the treatment of various cancers. Omeros Corporation was incorporated in 1994 and is headquartered in Seattle, Washington.

Paratek Pharmaceuticals NASDAQ:PRTK

Paratek Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on the development and commercialization of life-saving therapies for life-threatening diseases or other public health threats for civilian, government, and military use. Its products include NUZYRA, a once-daily oral and intravenous broad-spectrum antibiotic for the treatment of adult patients with community-acquired bacterial pneumonia, and acute skin and skin structure infections caused by susceptible pathogens; and SEYSARA, a once-daily oral therapy for the treatment of moderate to severe acne vulgaris. The company has license and collaboration agreements with Zai Lab (Shanghai) Co., Ltd. and Allergan plc; license agreement with Tufts University to develop and commercialize products for the treatment or prevention of bacterial or microbial diseases, or medical conditions; and contract with Biomedical Advanced Research and Development Authority to support the development of NUZYRA for the treatment of pulmonary anthrax. It also has license agreement with Tetraphase Pharmaceuticals, Inc. to develop, import, and sell the XERAVATM product, which is used for the treatment of complicated intra-abdominal infections caused by bacteria. The company was founded in 1996 and is headquartered in Boston, Massachusetts.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time